CAS 87805-34-3

peptide simile al glucagone I umano

Descrizione:

Il peptide simile al glucagone-1 (GLP-1) è un ormone peptidico che svolge un ruolo cruciale nel metabolismo del glucosio e nella regolazione dell'appetito. Viene prodotto nell'intestino in risposta all'assunzione di cibo ed è noto per la sua capacità di aumentare la secrezione di insulina dal pancreas, inibire il rilascio di glucagone e rallentare lo svuotamento gastrico, contribuendo così a livelli più bassi di glucosio nel sangue. La forma umana del GLP-1, con il numero CAS 87805-34-3, è composta da 30 aminoacidi ed è caratterizzata dalla sua attività biologica, che include la promozione della sazietà e la riduzione dell'assunzione di cibo. Inoltre, il GLP-1 ha effetti neuroprotettivi ed è oggetto di studio per le sue potenziali applicazioni terapeutiche nel trattamento del diabete di tipo 2 e dell'obesità. La sua stabilità nel flusso sanguigno è limitata a causa della rapida degradazione da parte dell'enzima dipeptidil peptidasi-4 (DPP-4), portando allo sviluppo di agonisti del recettore GLP-1 che imitano la sua azione fornendo effetti di lunga durata. In generale, il GLP-1 è un componente vitale del sistema endocrino del corpo, influenzando sia le funzioni metaboliche che quelle neurologiche.

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

InChI: InChI=1/C186H275N51O59/c1-17-94(10)149(182(294)209-98(14)155(267)220-128(73-105-78-199-111-42-28-27-41-109(105)111)171(283)223-123(68-91(4)5)173(285)234-147(92(6)7)180(292)219-113(43-29-31-63-187)158(270)200-81-136(245)210-112(45-33-65-197-185(191)192)157(269)203-84-146(262)263)236-174(286)126(70-102-37-23-19-24-38-102)225-165(277)120(55-61-142(254)255)216-162(274)114(44-30-32-64-188)212-153(265)96(12)206-152(264)95(11)207-161(273)118(51-57-135(190)244)211-137(246)82-201-160(272)117(53-59-140(250)251)215-168(280)122(67-90(2)3)222-170(282)125(72-104-47-49-108(243)50-48-104)226-177(289)132(85-238)230-179(291)134(87-240)231-181(293)148(93(8)9)235-176(288)131(77-145(260)261)228-178(290)133(86-239)232-184(296)151(100(16)242)237-175(287)127(71-103-39-25-20-26-40-103)229-183(295)150(99(15)241)233-138(247)83-202-159(271)116(52-58-139(248)249)213-154(266)97(13)208-167(279)129(75-107-80-196-89-205-107)227-163(275)115(46-34-66-198-186(193)194)214-164(276)119(54-60-141(252)253)217-169(281)124(69-101-35-21-18-22-36-101)224-166(278)121(56-62-143(256)257)218-172(284)130(76-144(258)259)221-156(268)110(189)74-106-79-195-88-204-106/h18-28,35-42,47-50,78-80,88-100,110,112-134,147-151,199,238-243H,17,29-34,43-46,51-77,81-87,187-189H2,1-16H3,(H2,190,244)(H,195,204)(H,196,205)(H,200,270)(H,201,272)(H,202,271)(H,203,269)(H,206,264)(H,207,273)(H,208,279)(H,209,294)(H,210,245)(H,211,246)(H,212,265)(H,213,266)(H,214,276)(H,215,280)(H,216,274)(H,217,281)(H,218,284)(H,219,292)(H,220,267)(H,221,268)(H,222,282)(H,223,283)(H,224,278)(H,225,277)(H,226,289)(H,227,275)(H,228,290)(H,229,295)(H,230,291)(H,231,293)(H,232,296)(H,233,247)(H,234,285)(H,235,288)(H,236,286)(H,237,287)(H,248,249)(H,250,251)(H,252,253)(H,254,255)(H,256,257)(H,258,259)(H,260,261)(H,262,263)(H4,191,192,197)(H4,193,194,198)/t94-,95-,96-,97-,98-,99?,100?,110-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,147-,148-,149-,150-,151-/m0/s1

SMILES: CC[C@H](C)[C@@H](C(=N[C@@H](C)C(=N[C@@H](Cc1c[nH]c2ccccc12)C(=N[C@@H](CC(C)C)C(=N[C@@H](C(C)C)C(=N[C@@H](CCCCN)C(=NCC(=N[C@@H](CCCNC(=N)N)C(=NCC(=O)O)O)O)O)O)O)O)O)O)N=C([C@H](Cc1ccccc1)N=C([C@H](CCC(=O)O)N=C([C@H](CCCCN)N=C([C@H](C)N=C([C@H](C)N=C([C@H](CCC(=N)O)N=C(CN=C([C@H](CCC(=O)O)N=C([C@H](CC(C)C)N=C([C@H](Cc1ccc(cc1)O)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C(C)C)N=C([C@H](CC(=O)O)N=C([C@H](CO)N=C([C@H](C(C)O)N=C([C@H](Cc1ccccc1)N=C([C@H](C(C)O)N=C(CN=C([C@H](CCC(=O)O)N=C([C@H](C)N=C([C@H](Cc1cnc[nH]1)N=C([C@H](CCCNC(=N)N)N=C([C@H](CCC(=O)O)N=C([C@H](Cc1ccccc1)N=C([C@H](CCC(=O)O)N=C([C@H](CC(=O)O)N=C([C@H](Cc1cnc[nH]1)N)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O

Sinonimi:

• Glucagon-like peptide I (1-37)
• Glp-I (1-37)
• Glucagon-related peptide I (ox)
• Glycine, L-histidyl-L-alpha-aspartyl-L-alpha-glutamyl-L-phenylalanyl-L-alpha-glutamyl-L-arginyl-L-histidyl-L-alanyl-L-alpha-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-alpha-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-alpha-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-Llysylglycyl-L-arginyl-
• Glp-1

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat)

CAS: 87805-34-3

Glucagon-Like Peptide 1 (GLP-1) is synthesized by posttranslational processing of proglucagon in the intestine and pancreas and plays an important role in metabolic homeostasis. Among the different molecular forms, such as GLP-1 (7-36) amide and GLP-1 (7-37), the function of GLP-1 (1-37) has been unclear. GLP-1 (1-37) was shown to convert intestinal epithelial cells into insulin-producing cells. These observations turned GLP-1 (1-37) into a new promising therapeutic compound for the treatment of diabetes mellitus. In animal models of dilated cardiomyopathy, hypertensive heart failure, and myocardial infarction, GLP-1 has shown a remarkable cardioprotective activity.

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Purezza: 97.1%

Colore e forma: White Lyophilisate

Peso molecolare: 4169.54

Ref: 01-4037542

Glucagon-like peptide 1 (1-37), human

CAS: 87805-34-3

Human GLP-1 (1-37) is a potent GLP-1 receptor agonist without impact on rat food intake or insulin secretion.

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Purezza: 98%

Colore e forma: Solid

Peso molecolare: 4169.48

Ref: TM-TP1148

Glucagon-like peptide I (human)(GLP-I,1-37) Trifluoroacetate

CAS: 87805-34-3

Formula: C₁₈₆H₂₇₅N₅₁O₅₉·C₂HF₃O₂

Peso molecolare: 4169.54

Ref: 4Z-PG-194024

HuGLP-1

CAS: 87805-34-3

HuGLP-1

Colore e forma: White Lyophilised Powder

Ref: 54-BITH3020

GLP-1 (1-37)

CAS: 87805-34-3

Glucagon-like peptide (GLP) 1 is a post-translationally modified version of proglucagon. GLP-1 (1-37) is a naturally produced analog of GLP-1. Unlike truncated GLP-1, GLP-1 (1-37) does not alter food intake in rat models or pancreatic insulin secretion. GLP-1 (1-37) can induce insulin production in developing adult intestinal cells via upregulation of the ngn3 gene and its downstream targets. This can restore glucose homeostasis when implanted into diabetic mice. GLP-1 (1-37) may offer a  future treatment for diabetes mellitus. GLP-1 (1-37) can also inhibit chemokine-induced migration of human CD4-positive lymphocytes, an early step in atherogenesis. This raises the possibility that GLP-1 (1-37) is part of a novel mechanism to modulate vascular disease.

Peso molecolare: 4,169.54 g/mol

Ref: 3D-CRB1001037

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat)

CAS: 87805-34-3

Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Peso molecolare: 4,169.54 g/mol

Ref: 3D-PP50515

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

CAS: 87805-34-3

GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt is a posttranslational modification of the endogenous human hormone GLP-1. It is a synthetic form of this hormone that has been modified to allow for improved stability and solubility. This peptide is found in the pancreatic alpha cells and intestinal L cells and stimulates the release of insulin from pancreatic beta cells. GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt has also been shown to increase glucose uptake by muscle tissue as well as stimulate the release of incretin hormones such as glucagon-like peptide 1 and gastric inhibitory polypeptide. GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt

Formula: C₁₈₆H₂₇₅N₅₁O₅₉

Purezza: Min. 95%

Peso molecolare: 4,169.48 g/mol

Ref: 3D-FG109540